SCHOTT FRANCE PHARMA SYSTEMS : revenue, balance sheet and financial ratios

SCHOTT FRANCE PHARMA SYSTEMS is a French company founded 65 years ago, specialized in the sector Fabrication et façonnage d'autres articles en verre, y compris verre technique. Based in PONT-SUR-YONNE (89140), this company of category ETI shows in 2025 a revenue of 25.1 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SCHOTT FRANCE PHARMA SYSTEMS (SIREN 706180056)
Indicator 2025 2024 2023 2022 2021 2020 2019 2018 2016
Revenue 25 082 444 € 24 481 675 € 22 856 955 € 19 409 087 € 19 951 238 € 22 701 069 € 22 379 606 € 21 936 455 € 21 675 923 €
Net income -1 338 002 € -613 423 € -1 593 245 € -2 496 317 € -1 939 144 € -478 085 € -529 778 € -253 388 € -452 961 €
EBITDA 756 557 € 1 149 586 € -516 755 € -1 653 535 € -1 076 093 € 28 104 € 169 845 € 853 044 € 578 179 €
Net margin -5.3% -2.5% -7.0% -12.9% -9.7% -2.1% -2.4% -1.2% -2.1%

Revenue and income statement

In 2025, SCHOTT FRANCE PHARMA SYSTEMS achieves revenue of 25.1 M€. Revenue is growing positively over 9 years (CAGR: +1.6%). Vs 2024: +2%. After deducting consumption (7.2 M€), gross margin stands at 17.9 M€, i.e. a rate of 71%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 757 k€, representing 3.0% of revenue. The operating margin remains fragile, requiring cost vigilance. Net income is negative at -1.3 M€ (-5.3% of revenue), which will impact equity.

Revenue (2025) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

25 082 444 €

Gross margin (2025) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

17 891 012 €

EBITDA (2025) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

756 557 €

EBIT (2025) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

-801 942 €

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

-1 338 002 €

EBITDA margin (2025) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

3.0%

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 3%. Low autonomy: the company heavily depends on external financing (banks, suppliers). Cash flow represents 0.1% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

0.0%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

3.138%

Cash flow / Revenue (2025) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

0.132%

Repayment capacity (2025) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

0.0

Asset age ratio (2025) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

28.4%

Solvency indicators evolution
SCHOTT FRANCE PHARMA SYSTEMS

Sector positioning

Debt ratio
0.0 2025
2023
2024
2025
Q1: 4.77
Med: 18.88
Q3: 182.59
Excellent -22 pts over 3 years

In 2025, the debt ratio of SCHOTT FRANCE PHARMA SYSTEMS (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.

Financial autonomy
3.14% 2025
2023
2024
2025
Q1: 11.93%
Med: 42.56%
Q3: 67.14%
Watch

In 2025, the financial autonomy of SCHOTT FRANCE PHARMA SYSTEMS (3.1%) ranks in the bottom 25% of the sector. This ratio represents the share of equity in total financing. Low autonomy may limit investment capacity and increase vulnerability.

Repayment capacity
0.0 years 2025
2023
2024
2025
Q1: 0.19 years
Med: 0.3 years
Q3: 0.99 years
Excellent -23 pts over 3 years

In 2025, the repayment capacity of SCHOTT FRANCE PHARMA SYSTEMS (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 53.55. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 73.0x. Operating income very largely covers interest expenses: high safety margin.

Liquidity ratio (2025) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

53.554

Interest coverage (2025) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

73.012

Liquidity indicators evolution
SCHOTT FRANCE PHARMA SYSTEMS

Sector positioning

Liquidity ratio
53.55 2025
2023
2024
2025
Q1: 159.16
Med: 252.9
Q3: 413.23
Watch

In 2025, the liquidity ratio of SCHOTT FRANCE PHARMA SYSTEMS (53.55) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.

Interest coverage
73.01x 2025
2023
2024
2025
Q1: 0.0x
Med: 1.11x
Q3: 7.23x
Excellent +96 pts over 3 years

In 2025, the interest coverage of SCHOTT FRANCE PHARMA SYSTEMS (73.0x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 53 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 75 days. Favorable situation: supplier credit is longer than customer credit by 22 days. Inventory turnover is 70 days (= Average inventory / Cost of goods x 360). WCR is negative (-62 days): operations structurally generate cash. Notable WCR improvement over the period (-274%), freeing up cash.

Operating WCR (2025) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

-4 340 015 €

Customer credit (2025) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

53 j

Supplier credit (2025) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

75 j

Inventory turnover (2025) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

70 j

WCR in days of revenue (2025) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

-62 j

WCR and payment terms evolution
SCHOTT FRANCE PHARMA SYSTEMS

Positioning of SCHOTT FRANCE PHARMA SYSTEMS in its sector

Comparison with sector Fabrication et façonnage d'autres articles en verre, y compris verre technique

Valuation estimate

Based on 228 transactions of similar company sales (all years), the value of SCHOTT FRANCE PHARMA SYSTEMS is estimated at 1 933 584 € (range 1 058 415€ - 5 469 546€). With an EBITDA of 756 557€, the sector multiple of 1.5x is applied. The price/revenue ratio is 0.13x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2025
228 transactions
1058k€ 1933k€ 5469k€
1 933 584 € Range: 1 058 415€ - 5 469 546€
Section all-time Aggregated at NAF section level

Valuation detail by method

Ajustez les pondérations selon votre analyse

EBITDA Multiple 50%
756 557 € × 1.5x
Estimation 1 166 013 €
363 634€ - 3 018 982€
Revenue Multiple 30%
25 082 444 € × 0.13x
Estimation 3 212 870 €
2 216 385€ - 9 553 819€
How is this estimate calculated?

This estimate is based on the analysis of 228 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Fabrication et façonnage d'autres articles en verre, y compris verre technique)

Compare SCHOTT FRANCE PHARMA SYSTEMS with other companies in the same sector:

Voir toutes les statistiques du secteur Fabrication et façonnage d'autres articles en verre, y compris verre technique

Frequently asked questions about SCHOTT FRANCE PHARMA SYSTEMS

What is the revenue of SCHOTT FRANCE PHARMA SYSTEMS ?

The revenue of SCHOTT FRANCE PHARMA SYSTEMS in 2025 is 25.1 M€.

Is SCHOTT FRANCE PHARMA SYSTEMS profitable?

SCHOTT FRANCE PHARMA SYSTEMS recorded a net loss in 2025.

Where is the headquarters of SCHOTT FRANCE PHARMA SYSTEMS ?

The headquarters of SCHOTT FRANCE PHARMA SYSTEMS is located in PONT-SUR-YONNE (89140), in the department Yonne.

Where to find the tax return of SCHOTT FRANCE PHARMA SYSTEMS ?

The tax return of SCHOTT FRANCE PHARMA SYSTEMS is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SCHOTT FRANCE PHARMA SYSTEMS operate?

SCHOTT FRANCE PHARMA SYSTEMS operates in the sector Fabrication et façonnage d'autres articles en verre, y compris verre technique (NAF code 23.19Z). See the 'Sector positioning' section above to compare the company with its competitors.